The estimated Net Worth of Garrett Nichols is at least $309 Tysiąc dollars as of 7 February 2020. Garrett Nichols owns over 11,355 units of Chimerix Inc stock worth over $223,657 and over the last 10 years Garrett sold CMRX stock worth over $85,152.
Garrett has made over 2 trades of the Chimerix Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Garrett sold 11,355 units of CMRX stock worth $19,190 on 7 February 2020.
The largest trade Garrett's ever made was selling 30,680 units of Chimerix Inc stock on 7 January 2020 worth over $65,962. On average, Garrett trades about 2,102 units every 2 days since 2014. As of 7 February 2020 Garrett still owns at least 260,066 units of Chimerix Inc stock.
You can see the complete history of Garrett Nichols stock trades at the bottom of the page.
Garrett's mailing address filed with the SEC is C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC, 27713.
Over the last 12 years, insiders at Chimerix Inc have traded over $133,441,183 worth of Chimerix Inc stock and bought 1,129,869 units worth $4,757,752 . The most active insiders traders include Patrick Machado, Pharmaceuticals, Inc. Cantex oraz Ernest Mario. On average, Chimerix Inc executives and independent directors trade stock every 25 days with the average trade being worth of $72,060. The most recent stock trade was executed by Michael T. Andriole on 8 August 2024, trading 1,285 units of CMRX stock currently worth $1,067.
led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed
Chimerix Inc executives and other stock owners filed with the SEC include: